Infinity Pharmaceuticals, Inc.
Infinity Pharmaceuticals, Inc. (INFIQ) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
infiq · stock forecast · 14 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 14 Wall Street analysts in the past 3 months
Hold
14 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $0.00
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $0.00 | ↑ 0.00% |
1-day model range: $0–$0. Peak: $0 (+0.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · INFIQ · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2023-02-24 | Piper Sandler | Downgrade ↓ | Overweight→Neutral |
| 2022-11-16 | B. Riley Securities | Downgrade ↓ | Buy→Neutral |
| 2022-05-23 | Piper Sandler | Maintains | Overweight→Overweight |
| 2022-03-31 | Truist Securities | Maintains | Buy→Buy |
| 2022-03-30 | Piper Sandler | Maintains | Overweight→Overweight |
| 2021-08-02 | JP Morgan | Upgrade ↑ | Neutral→Overweight |
| 2021-07-28 | Wells Fargo | Upgrade ↑ | Equal Weight→Overweight |
| 2021-03-17 | Wells Fargo | Maintains | Equal Weight→Equal Weight |
| 2021-02-05 | JP Morgan | Upgrade ↑ | Underweight→Neutral |
| 2020-05-18 | B. Riley Securities | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Infinity Pharmaceuticals, Inc. (INFIQ) stock. Of the recent 46 rating actions, 11 were upgrades and 13 were downgrades. 14 analysts currently cover INFIQ.
Analyst Recommendation Trends
INFIQ analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$3M
↑ 0.0% YoY
Revenue Next Year
$4M
↑ 29.6% YoY
EPS This Year
$-0.46
EPS Next Year
$-0.55
↑ 19.6% YoY
EPS ForecastReported vs Estimated
Analysts forecast INFIQ EPS of $-0.46 for the current fiscal year, based on estimates from 1 analysts. The INFIQ revenue forecast is $3M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The INFIQ stock forecast is supported by two independent data sources: analyst consensus ratings from 14 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus INFIQ price target is $0.00 (+0.0% upside), with an analyst consensus of Hold.
The INFIQ short-term stock prediction for tomorrow is $0.00 (+0.00%).
Infinity Pharmaceuticals, Inc. trades on OTC under the ticker INFIQ. The INFIQ stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 36% of covering analysts.
Frequently asked questions
INFIQ forecast · 8 questionsAccording to 14 Wall Street analysts, the average 12-month INFIQ price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $0.00.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.